Atopic dermatitis: a comprehensive updated review of this intriguing disease with futuristic insights
Top Cited Papers
Open Access
- 7 February 2025
- journal article
- review article
- Published by Springer Nature in Inflammopharmacology
- Vol. 33 (3) , 1161-1187
Abstract
Atopic dermatitis (AD) is a paradigmatic prevalent, long-lasting, and inflammatory skin condition with a diverse range of clinical manifestations. The etiology and clinical symptoms of AD are influenced by complex pathophysiological processes, which involve a strong genetic component, epidermal dysfunction, and immunological dysregulation, and a strong influence of other physiological and environmental factors. The FDA has approved targeted and well-tolerated immunomodulators including biologics like dupilumab and crisaborole, and small molecules such as baricitinib, as novel therapies for AD. They effectively treat AD but are too expensive for most patients. The review provides an update on the state of knowledge of AD pathogenesis, discusses the available diagnostic and scoring indices, and provides a scientific foundation for treatment methods for AD. This review also presents data on clinical efficacy of innovative treatments’ considering recent guidelines, emphasizing the newest medications and ongoing trials. Finally, the new implication of artificial intelligence (AI) in AD management is explored, where AI can speed up diagnosis and therapy. The PubMed, Google Scholar, and ScienceDirect databases were used for this review. Graphical AbstractKeywords
Funding Information
- National Research Centre Egypt
This publication has 162 references indexed in Scilit:
- Cendakimab in Patients With Moderate to Severe Atopic DermatitisJAMA Dermatology, 2024
- Atopic dermatitis: treatment and innovations in immunotherapyInflammopharmacology, 2024
- Live Biotherapeutic Products and Probiotics for the SkinAdvanced NanoBiomed Research, 2021
- Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic DermatitisJAMA Dermatology, 2021
- Atopic dermatitis: Tofacitinib, an option for refractory diseaseClinical Case Reports, 2020
- Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic DermatitisJAMA Dermatology, 2020
- Clinical relevance of eosinophils, basophils, serum total IgE level, allergen‐specific IgE, and clinical features in atopic dermatitisJournal of Clinical Laboratory Analysis, 2020
- Application of Topical Phosphodiesterase 4 Inhibitors in Mild to Moderate Atopic DermatitisJAMA Dermatology, 2019
- Respiratory viral infections and atopic development: From possible mechanisms to advances in treatmentEuropean Journal of Immunology, 2018
- Proteolytic Activity of Staphylococcus aureus Strains Isolated from the Colonized Skin of Patients with Acute-Phase Atopic DermatitisEuropean Journal of Clinical Microbiology & Infectious Diseases, 2002